5 Results for "

antigen presentation studies

" in MedChemExpress (MCE) Product Catalog:
Products (5)

5 Results for "antigen presentation studies" in MCE Product Catalog:

Cat. No.: HY-112026
CAS No.: 6240-11-5
Purity:  99.82%
Target:  

MHC

Research Areas:  

Inflammation/Immunology Cancer

1-Adamantaneethanol is an allele-selective MHC II class molecule loading enhancer (MHC loading enhancer, MLE) that enhances peptide loading and ligand exchange of HLA-DR molecules. 1-Adamantaneethanol targets the polymorphic P1 pocket of HLA-DR molecules and preferentially acts on HLA-DR subtypes with Gly at position β86, thereby stabilizing the peptide-receptor conformation and accelerating antigen loading. 1-Adamantaneethanol can be used in studies related to MHC II antigen presentation, peptide vaccines, adaptive immunity and tumor immunity .
loading...
    loading...
Cat. No.: HY-176755
CAS No.: 943316-60-7
Research Areas:  

Inflammation/Immunology

CCL-34 is a Toll-like receptor 4 (TLR4) activator. CCL-34 significantly induced dendritic cell (DC) CD83 expression and IL-12p70 production in a dose-dependent manner, thereby inducing DC maturation. CCL-34 enhanced the allostimulatory activity of DC on naive CD4+CD45+RA+ T cell proliferation and IFN-γ secretion. CCL-34 further induced antigen presentation ability in mice inoculated with doxorubicin-treated colorectal cancer cells. CCL-34 can be used in studies of immune stimulation.
loading...
    loading...
Cat. No.: HY-P5488
CAS No.: 329696-53-9
Target:  

Inhibitory Antibodies

Research Areas:  

Others

BDC2.5 Mimotope 1040-63 is a biological active peptide. (The TCR transgenic model (BDC2.5) mimitope was used in type 1 diabetes (T1D) study. T1D is an autoimmune disease in which T cells mediate damage to pancreatic islet b cells. T1D is caused by autoreactive T cell destruction of insulin-producing cells. BDC2.5 mimotope was utilized to support the study on antigen presentation of antigenic peptides to islet autoantigen-specific T cells.)
loading...
    loading...
Cat. No.: HY-117573
CAS No.: 1438280-73-9
1Z105 is an orally active TLR4/MD2 agonist, immunostimulant and vaccine adjuvant. 1Z105 activates NF-κB via the MyD88/TRIF pathway in a CD14-independent manner, with EC50 values of 0.63 µM and 0.77 µM for inducing IL-6 and IL-12 in mBMDCs, respectively. 1Z105 promotes dendritic cell maturation, antigen uptake and cross-presentation; when used alone, it induces Th2-IgG1, while combined with the TLR7 agonist 1V270, it synergistically induces balanced Th1/Th2 responses and provides low-reactogenic protection against homologous, heterologous and heterosubtypic influenza. 1Z105 prevents LPS (HY-D1056A1)- and galactosamine-induced liver injury as well as autoantibody-driven arthritis in mice. 1Z105 can be used in studies related to influenza virus infection, inflammation, and LPS/galactosamine-induced liver injury .
loading...
    loading...
Cat. No.: HY-P990716
CAS No.: 2648346-74-9
Synonyms: AZD7789

Target:  

PD-1/PD-L1 Tim3

Research Areas:  

Inflammation/Immunology

Sabestomig (AZD7789) is a monovalent bispecific antibody targeting PD-1 and TIM-3. Sabestomig binds to PD-1 and an epitope in the TIM-3 IgV domain outside the phosphatidylserine-binding cleft, thereby precisely regulating immune responses. Sabestomig promotes IL-2 production, efferocytosis and cross-presentation of tumor antigens, and enhances the release of anti-tumor T cell cytokines, cytotoxicity, and secretion of IFN-γ. Sabestomig inhibits the growth of solid tumors, prolongs the duration of tumor suppression, and significantly enhances anti-tumor responses following anti-PD-1 therapy. Sabestomig has been used in studies related to non-small cell lung cancer and classical Hodgkin lymphoma .
loading...
    loading...